Table 4.
Combined Heart–Liver Transplantation (CHLT) Single-Center Outcomes.
| Citation | Year | Successful CHLT Completed | Perioperative Transfusion | Post-op Dialysis | Infection | DVT/PE | Return to OR for Bleeding | Duration of Mechanical Ventilation | LOS ICU | LOS Hospital | In-Hospital Mortality | Survival | Follow-up Time | Readmission | Rejection |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barbara et al. [7] | 2015 | 27 CHLT, 4 also with kidney | 7 patients with pre-op transfusions of blood products, RBC mean 3.2 ± 5.4 U, FFP mean 1.8 ± 5.0, Platelets mean 0.7 +/0 1.6, Cryoprecipitate mean 0.6 + −2.1 | 5/27 (18.5%) | NR | NR | NR | Mean 1.8 ± 2 | Mean 8.5 ± 7.1 | Mean 24.6 ± 27.8 | 0 (0%) | 30-day Survival: 25/26 (96.2%) | NR | NR | NR |
| Atluri et al. [31] | 2014 | 26/26 (100%) | 23 of 26 patients required transfusion of PRBC, mean 4 ± 4 U in the postoperative period | NR | 3.8 (1%) | NR | 3.8 (1%) | Mean 3 ± 2 | Mean 10 ± 5 days | Mean 25 ± 11 days | NR | 30-day mortality 3.8%, 1-Year Patient Survival: 87% ± 7%, 5-Year Patient Survival: 83% +/1 3% | NR | NR | “Long term” Rejection 3/26 (11.5%) |
| Nagpal et al. [29] | 2013 | 5/5 (100%) | NR | 1/5 (20%) | 2/5 (40%) | 1/5 DVT (20%) | 1/5 (20%) | Median 2 days (1 to 8) | Median 3 (R 3–11 days) | 26 days (12–80 days) | 0 (0%) | 30-day Survival 100%, Survival 100% at mean 38 ± 20 months | 38 ± 20 months | 1/5 (at 15 months post-op) | 0 (0%) |
| Nelson et al. [9] | 2012 | 6/7 (86%) and 1 Lung Followed By Liver | NR | 3/7 (42.9%) | 2 CMV, 2 sepsis, 1 Aspergillus | NR | NR | NR | NR | NR | 0 (0%) | 30-day Survival: 100%, 1-Year Survival: 71%, 4.5 Years Patient Survival: 71%, 4.5 Year Graft Survival: 71% | Mean 55 months | NR | 4/7 (57%) patients had 15 episodes of rejection |
| Eyraud et al. [33] | 2011 | 3/3 (100%) | Mean: 12 U PRBC, 0 U FFP | NR | NR | NR | NR | NR | NR | NR | 0 (0%) | 30-day Survival: 100%, 1-year Survival: 100% | Mean 26 months (Range 12–38) | NR | NR |
| Rauchfuss et al. [36] | 2011 | 4/4 (100%) | NR | 4/4 (100%) | NR | NR | 2/4 (50%) | 1, 3, 35 | NR | NR | 1/4 (25%) | 11 months, 25 months, 61 months | 11 months, 25 months, 61 months | NR | NR |
| Raichlin et al. [15] | 2009 | 13/15 (86.6%) | NR | 2/13 (15.3%) | 5/13 (39%) | 1/13 PE (7.7%) | 2/4 (50%) | NR | 13.8 ± 12.1 days | 26.5 ± 20.9 | NR | 1-Year Patient Survival 100%, 5-Year Patient Survival 75%, 10-Year Patient Survival 60% | Mean follow-up 61.6 ± 53.6 months | NR | Cardiac rejection: 8 patients, Liver rejection: 1 patient |
| Pilato et al. [10] | 2007 | 5/5 (100%) | NR | NR | NR | NR | NR | NR | 1, 4, 5 days | NR | 1/5 (20%) | 30-day Survival 100%, 1-Year Survival 80% | NR | NR | NR |
| Nardo et al. [12] | 2004 | 4/4 (100%) | Intraoperative PRBC: 5500, 6300, 4990, 1800, Intraoperative FFP: 5550, 7350, 2800, 4200 | 1/4 (25%) | NR | NR | NR | NR | 6 days, 6 days, 13 days, 60 days | 22 days, 24 days, 90 days | 1/4 (25%) | Pt. 1 alive at 38 months, Pt. 2 died at 2 days, Pt. 3 dead at 20 months, Pt. 4 alive at 1 months | NR | NR | 2/4 (50%) |